Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

899
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
899

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Diagnostic Yield in Shape-Sensing Robotic-Assisted Bronchoscopy (ssRAB): A Retrospective Single-Center Study.

Diagnostics (Basel, Switzerland)·2026
Same author

External validation of the P-Score in the prospective, pre-biopsy DEPROMP cohort: integrated mpMRI and PSMA PET/CT risk stratification for prostate cancer detection.

European journal of nuclear medicine and molecular imaging·2026
Same author

Habenula volume alterations in adults born very preterm.

Scientific reports·2026
Same author

Downregulation of cytokine responses and STAT signaling in children with sickle cell disease.

Scientific reports·2026
Same author

Reply to Emre Karabay's Letter to the Editor re: Ritter Manuel, Stein Johannes, Barber Neil, et al. WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms. Eur Urol Focus 2026;12:266-74.

European urology focus·2026
Same author

Learning Curve of Shape-Sensing Robotic-Assisted Bronchoscopy (ssRAB) for Peripheral Pulmonary Lesions in a Thoracic Surgery Center Using the ION System.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 4, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

1.9K

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.

Jonas Saal1,2,3, Markus Eckstein4,5,6, Manuel Ritter3,7

  • 1Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.

JAMA Oncology
|December 26, 2024
PubMed
Summary

A new risk classification system for progressive disease (PD) in patients receiving immunotherapy was developed. This system, based on PD patterns, accurately predicts postprogression survival (PPOS) across various solid tumors.

More Related Videos

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

9.5K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.3K

Related Experiment Videos

Last Updated: Jun 4, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

1.9K
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

9.5K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.3K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trial Analysis

Background:

  • Immune checkpoint inhibitors (ICIs) show variable outcomes in patients with progressive disease (PD), challenging current RECIST criteria.
  • Existing methods for evaluating PD in ICI-treated patients do not fully capture outcome heterogeneity.

Purpose of the Study:

  • To develop and validate a novel PD classification system based on distinct PD patterns.
  • To assess the association between these PD patterns and postprogression survival (PPOS) in patients treated with atezolizumab.

Main Methods:

  • Analysis of data from 5 phase 3 clinical trials involving 1377 patients treated with atezolizumab.
  • Identification and categorization of seven PD patterns based on lesion progression and new lesion formation.
  • Development of a 3-tiered risk classification (low, intermediate, high) for PD.

Main Results:

  • Seven PD patterns significantly impacted prognosis in renal cell carcinoma (RCC).
  • A modified PD classification demonstrated a strong association with PPOS in ICI-treated RCC patients.
  • The developed risk score showed applicability across diverse solid tumors in validation analyses.

Conclusions:

  • A novel PD risk classification system based on lesion patterns has been developed and validated.
  • This classification system enhances prognostication and clinical decision-making for patients with PD receiving immunotherapy.
  • The findings offer a valuable tool for managing patients undergoing immunotherapy for various solid tumors.